ADAPT-TP trial analysis indicates that a pathological complete response to neoadjuvant therapy could help guide treatment decisions for early breast cancer patients

Phase II results indicate that the PD-1 inhibitor retifanlimab may be a feasible therapy for patients with advanced squamous carcinoma of the anal canal

Adjuvant nivolumab improves DFS over placebo for oesophageal and gastro-oesophageal junction cancer patients without a pathological complete response after neoadjuvant chemoradiotherapy and surgery

An antibody–drug conjugate has shown potential as a therapy for patients with recurrent or metastatic cervical cancer

Advanced non-small-cell lung cancer patients with PD-L1 tumour expression of at least 50% have better survival outcomes with cemiplimab than platinum-doublet chemotherapy

Adding abemaciclib to endocrine therapy may help to combat invasive disease recurrence among high-risk early breast cancer patients with HR-positive, HER2-negative disease

No disease-free survival benefit with use of postoperative radiotherapy for N2 completely resected non-small-cell lung cancer

Heavily pretreated, metastatic urothelial cancer patients may benefit from sacituzumab govitecan